Eintrag weiter verarbeiten
Chromatin Regulators as a Guide for Cancer Treatment Choice
Gespeichert in:
| Zeitschriftentitel: | Molecular Cancer Therapeutics |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Molecular Cancer Therapeutics, 15, 2016, 7, S. 1768-1777 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève |
|---|---|
| author |
Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève |
| spellingShingle |
Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève Molecular Cancer Therapeutics Chromatin Regulators as a Guide for Cancer Treatment Choice Cancer Research Oncology |
| author_sort |
gurard-levin, zachary a. |
| spelling |
Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-15-1008 <jats:title>Abstract</jats:title> <jats:p>The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio- and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators—factors involved in the establishment and maintenance of functional chromatin domains—can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with docetaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel high-responders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. Mol Cancer Ther; 15(7); 1768–77. ©2016 AACR.</jats:p> Chromatin Regulators as a Guide for Cancer Treatment Choice Molecular Cancer Therapeutics |
| doi_str_mv |
10.1158/1535-7163.mct-15-1008 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE1LTEwMDg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE1LTEwMDg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2016 |
| issn |
1535-7163 1538-8514 |
| issn_str_mv |
1535-7163 1538-8514 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
gurardlevin2016chromatinregulatorsasaguideforcancertreatmentchoice |
| publishDateSort |
2016 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Cancer Therapeutics |
| source_id |
49 |
| title |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_unstemmed |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_full |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_fullStr |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_full_unstemmed |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_short |
Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_sort |
chromatin regulators as a guide for cancer treatment choice |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1535-7163.mct-15-1008 |
| publishDate |
2016 |
| physical |
1768-1777 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio- and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators—factors involved in the establishment and maintenance of functional chromatin domains—can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with docetaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel high-responders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. Mol Cancer Ther; 15(7); 1768–77. ©2016 AACR.</jats:p> |
| container_issue |
7 |
| container_start_page |
1768 |
| container_title |
Molecular Cancer Therapeutics |
| container_volume |
15 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347750765953032 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:00:15.591Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Chromatin+Regulators+as+a+Guide+for+Cancer+Treatment+Choice&rft.date=2016-07-01&genre=article&issn=1538-8514&volume=15&issue=7&spage=1768&epage=1777&pages=1768-1777&jtitle=Molecular+Cancer+Therapeutics&atitle=Chromatin+Regulators+as+a+Guide+for+Cancer+Treatment+Choice&aulast=Almouzni&aufirst=Genevi%C3%A8ve&rft_id=info%3Adoi%2F10.1158%2F1535-7163.mct-15-1008&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347750765953032 |
| author | Gurard-Levin, Zachary A., Wilson, Laurence O.W., Pancaldi, Vera, Postel-Vinay, Sophie, Sousa, Fabricio G., Reyes, Cecile, Marangoni, Elisabetta, Gentien, David, Valencia, Alfonso, Pommier, Yves, Cottu, Paul, Almouzni, Geneviève |
| author_facet | Gurard-Levin, Zachary A., Wilson, Laurence O.W., Pancaldi, Vera, Postel-Vinay, Sophie, Sousa, Fabricio G., Reyes, Cecile, Marangoni, Elisabetta, Gentien, David, Valencia, Alfonso, Pommier, Yves, Cottu, Paul, Almouzni, Geneviève, Gurard-Levin, Zachary A., Wilson, Laurence O.W., Pancaldi, Vera, Postel-Vinay, Sophie, Sousa, Fabricio G., Reyes, Cecile, Marangoni, Elisabetta, Gentien, David, Valencia, Alfonso, Pommier, Yves, Cottu, Paul, Almouzni, Geneviève |
| author_sort | gurard-levin, zachary a. |
| container_issue | 7 |
| container_start_page | 1768 |
| container_title | Molecular Cancer Therapeutics |
| container_volume | 15 |
| description | <jats:title>Abstract</jats:title> <jats:p>The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio- and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators—factors involved in the establishment and maintenance of functional chromatin domains—can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with docetaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel high-responders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. Mol Cancer Ther; 15(7); 1768–77. ©2016 AACR.</jats:p> |
| doi_str_mv | 10.1158/1535-7163.mct-15-1008 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xNTM1LTcxNjMubWN0LTE1LTEwMDg |
| imprint | American Association for Cancer Research (AACR), 2016 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2016 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1535-7163, 1538-8514 |
| issn_str_mv | 1535-7163, 1538-8514 |
| language | English |
| last_indexed | 2024-03-01T18:00:15.591Z |
| match_str | gurardlevin2016chromatinregulatorsasaguideforcancertreatmentchoice |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 1768-1777 |
| publishDate | 2016 |
| publishDateSort | 2016 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Molecular Cancer Therapeutics |
| source_id | 49 |
| spelling | Gurard-Levin, Zachary A. Wilson, Laurence O.W. Pancaldi, Vera Postel-Vinay, Sophie Sousa, Fabricio G. Reyes, Cecile Marangoni, Elisabetta Gentien, David Valencia, Alfonso Pommier, Yves Cottu, Paul Almouzni, Geneviève 1535-7163 1538-8514 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1535-7163.mct-15-1008 <jats:title>Abstract</jats:title> <jats:p>The limited capacity to predict a patient's response to distinct chemotherapeutic agents is a major hurdle in cancer management. The efficiency of a large fraction of current cancer therapeutics (radio- and chemotherapies) is influenced by chromatin structure. Reciprocally, alterations in chromatin organization may affect resistance mechanisms. Here, we explore how the misexpression of chromatin regulators—factors involved in the establishment and maintenance of functional chromatin domains—can inform about the extent of docetaxel response. We exploit Affymetrix and NanoString gene expression data for a set of chromatin regulators generated from breast cancer patient-derived xenograft models and patient samples treated with docetaxel. Random Forest classification reveals specific panels of chromatin regulators, including key components of the SWI/SNF chromatin remodeler, which readily distinguish docetaxel high-responders and poor-responders. Further exploration of SWI/SNF components in the comprehensive NCI-60 dataset reveals that the expression inversely correlates with docetaxel sensitivity. Finally, we show that loss of the SWI/SNF subunit BRG1 (SMARCA4) in a model cell line leads to enhanced docetaxel sensitivity. Altogether, our findings point toward chromatin regulators as biomarkers for drug response as well as therapeutic targets to sensitize patients toward docetaxel and combat drug resistance. Mol Cancer Ther; 15(7); 1768–77. ©2016 AACR.</jats:p> Chromatin Regulators as a Guide for Cancer Treatment Choice Molecular Cancer Therapeutics |
| spellingShingle | Gurard-Levin, Zachary A., Wilson, Laurence O.W., Pancaldi, Vera, Postel-Vinay, Sophie, Sousa, Fabricio G., Reyes, Cecile, Marangoni, Elisabetta, Gentien, David, Valencia, Alfonso, Pommier, Yves, Cottu, Paul, Almouzni, Geneviève, Molecular Cancer Therapeutics, Chromatin Regulators as a Guide for Cancer Treatment Choice, Cancer Research, Oncology |
| title | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_full | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_fullStr | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_full_unstemmed | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_short | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| title_sort | chromatin regulators as a guide for cancer treatment choice |
| title_unstemmed | Chromatin Regulators as a Guide for Cancer Treatment Choice |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1535-7163.mct-15-1008 |